Neurofibromatoses
Showing 1 - 25 of 202
Parenting, Alopecia, Skin Condition Trial in Cardiff (Mindful Parenting Programme)
Recruiting
- Parenting
- +6 more
- Mindful Parenting Programme
-
Cardiff, United KingdomCardiff University
Mar 9, 2023
US Selumetinib Registry
Not yet recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibromas
- (no location specified)
Jan 5, 2023
Mitochondrial Dysfunction in Neurofibromatosis Type 1
Not yet recruiting
- Neurofibromatosis 1
- Blood draw
- FACIT-F and Pain Scales
- (no location specified)
Jun 12, 2023
Natural History Study of Patients With Neurofibromatosis Type 2
Recruiting
- Neurofibromatosis
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Completed
- Neurofibromatosis Type 1
- Neurofibroma
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Advanced Data Analytics in Genetic Conditions
Not yet recruiting
- Neurofibromatosis
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Data Collected From Individuals Administered Neurobehavioral
Enrolling by invitation
- HIV
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
PASS of Paediatric Patients Initiating Selumetinib
Recruiting
- Neurofibromatosis Type 1
-
Angers, France
- +3 more
Jan 12, 2023
Neurofibromatosis 1 Trial in Boston (Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser)
Not yet recruiting
- Neurofibromatosis 1
- Deoxycholic Acid
- +3 more
-
Boston, MassachusettsWellman Center for Photomedicine
Nov 13, 2023
Studies in Patients With Tuberous Sclerosis Complex
Recruiting
- Tuberous Sclerosis Complex
-
Phoenix, ArizonaTranslational Genomics Research Institute (TGen)
Oct 18, 2022
(PRO) Measures for Individuals With Neurofibromatosis 1 and
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibromas
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)
Recruiting
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Recruiting
- Neurofibromatosis 2
- Bevacizumab Zirconium Zr-89
-
Leiden, Zuid-Holland, NetherlandsLeiden University Medical Center
Jan 5, 2023
Schwannomatosis, Schwannomas, Pain, Chronic Trial in Boston (Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo)
Not yet recruiting
- Schwannomatosis
- +2 more
- Siltuximab
- +3 more
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Jan 5, 2023
Neurofibromatosis 1, Neurofibroma, Plexiform Trial run by the NCI (Medication Event Monitoring System (MEMS))
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma, Plexiform
- Medication Event Monitoring System (MEMS)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group
Not yet recruiting
- Neurofibromatosis 1
- +2 more
- Test group (Group A): FCN-159 8 mg, orally, once daily;
- Control group (Group B): Placebo, orally, once daily;
- (no location specified)
Jun 16, 2023
Disfigurement From Photographs of Neurofibromatosis Type 1
Completed
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Development to Predict Malignant Conversion in Neurofibromatosis
Recruiting
- Neurofibromatosis 1
- +2 more
- Whole Body Magnetic Resonance Imaging
-
Baltimore, MarylandJohns Hopkins University
Dec 22, 2022
Cutaneous Neurofibromas in People With NF1
Recruiting
- Neurofibromatosis Type 1
- +3 more
- Evaluation of the natural history of cutaneous neurofibromas
-
Baltimore, MarylandJohns Hopkins University
Oct 12, 2022
Stressors in Parents of Cancer or Neurofibromatosis Type 1 (NF1)
Completed
- Parents of Children With Cancer
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)
Not yet recruiting
- Neurofibromatosis Type 1
- +2 more
- Selumetinib
- Placebo
-
Beijing, China
- +2 more
Apr 11, 2023
Leukemia, Juvenile Myelomonocytic, JMML, JCML Trial (Trametinib, Azacitidine, Fludarabine)
Not yet recruiting
- Leukemia, Juvenile Myelomonocytic
- +4 more
- Trametinib
- +3 more
- (no location specified)
May 4, 2023
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Cutaneous Neurofibroma Trial in Boston (Kybella, 980nm laser, 755nm Alexandrite Laser)
Recruiting
- Cutaneous Neurofibroma
- Kybella
- +3 more
-
Boston, MassachusettsWellman Center for Photomedicine, Massachusetts General Hospital
Aug 10, 2022